The U.S. women’s health market size was estimated at USD 22.50 billion in 2023 and is expected to grow at a CAGR of 4.04% from 2024 to 2030. Market growth can be attributed to the increasing geriatric women population, the growing prevalence of targeted diseases, such as osteoporosis, osteoarthritis, and menstrual health, and the introduction of novel medicines for women’s health. Furthermore, favorable policies by governments to improve women’s health and raise awareness are likely to drive the market during the forecast period.
In addition, permanent ovarian failure due to genetic changes, such as sex chromosome abnormalities, can cause premature menopause in approximately 1% of women aged below 40 years in the U.S. The majority of women use supplements and over-the-counter medicine brands, such as Midol, Advil, Aleve, Motrin, Pamprin, Tylenol, and Cora, to manage pain due to menopause. Thus, increasing awareness about the benefits of these OTC drugs and supplements to manage symptoms is expected to impact market growth positively. Additionally, with over 4 million live births being reported each year in the U.S., this corresponds to almost 600,000 PPD diagnoses. Several women who miscarry or have stillbirths experience PPD symptoms as well, including women who have miscarried or have had a stillbirth. In the U.S., around 900,000 women suffer from PPD annually.
Contraceptives play an important role in preventing unwanted pregnancies. Currently, there are no OTC pills available in the U.S. for controlling pregnancy. Thus, introducing OTC contraceptive pills in the U.S. is expected to contribute to market growth positively. For instance, in July 2022, HRA Pharma submitted its application to the U.S. FDA for Rx-to-OTC change for the Opill contraceptives for women. The successful approval of Opill can make it the first birth control contraceptive to be available OTC without prescription in the U.S. Thus, the wide availability of OTC contraceptives and vitamin supplements, such as One A Day Women’s Prenatal 1, Nature Made Prenatal Multi, Rainbow Light Prenatal One, & Vitamin Code Raw, is anticipated to drive the women’s health market over the forecast period.
Governments and private organizations across the globe are increasing their focus on women’s health, which is likely to drive the market over the forecast period. In developed economies, coverage provided to women is one of the key factors expected to drive the market. For instance, various coverage plans in the U.S. provide preventive services for women without copayment charges, which include folic acid supplements for women trying to get pregnant, contraceptives, and screening for breast cancer, anemia, & hepatitis B. In the U.S., the Department of Health and Human Services established Healthy People 2020, aimed at improving U.S. individuals' health over the decade.
The market growth stage is high, and the pace is accelerating. The women's health market is marked by significant innovation, spurred by swift technological progress. This advancement is fueled by next-generation contraceptives, AI-enhanced ultrasounds, and cutting-edge diagnostic tools.
The market is also characterized by a high level of merger and acquisition (M&A) activity by the leading players. This trend is driven by several factors, such as the pursuit of new technologies and talent acquisition, the imperative to consolidate in a swiftly expanding market, and the rising strategic significance of AI, among others.
Regulatory agencies such as the FDA and EMA play an important role in regulating the approval and commercialization of new women’s health products across the country. This trend reflects the growing recognition of the new product in the market.
This market has many product substitutes including lifestyle modifications, physical therapies, or complementary medicine approaches that can sometimes be used in place of pharmaceuticals for conditions like osteoporosis or menopausal symptoms.
The contraceptives segment held the highest revenue share of more than 35.76% of the Market revenue in 2023 due to the increase in Research & Development (R&D) activities and rising awareness about family planning among newly married people. For instance, researchers at the University of California recently developed a new drug that may replace daily contraceptive pills. Moreover, the rising support of major medical organizations, including the American College of Obstetricians & Gynecologists, the American Medical Association, and the Society for Adolescent Health & Medicine, and the American Academy of Family Physicians, to OTC oral contraception is also expected to drive segment growth.
The menopause segment is expected to grow at the highest CAGR rate over the forecast period. The growth can be attributed to the rising women population with menopause condition and the growing demand for its treatment. It is expected that every year, around 25 million women experience menopause globally, and by 2030, the total menopausal population is expected to be around 1.2 billion. In addition, about 75% of menopausal women experienced vasomotor symptoms and/or vaginal dryness. It can also lead to fluctuating estrogen levels, which is associated with various health conditions such as musculoskeletal health depletion and dementia. All these factors are expected to propel market growth over the forecast period.
The Prolia segment led the market in 2023, with a share of 19.92%, and is expected to grow at the fastest growth rate over the forecast period. Bone health issues and osteoporosis are different for women and young girls of various ethnic and ages backgrounds. Elder and Caucasian women who live in the U.S. are at high risk of developing osteoporosis due to lactose intolerant nature. According to the Bone Health and Osteoporosis, approximately 80% or 80 million women population suffer from osteoporosis in America. Women with small & thin bones and a decrease in estrogen levels are key possible reasons for high osteoporosis in women. Thus, the rising women population and the awareness about the benefits of treating with Prolia to cure disease is anticipated to boost segment growth over the forecast period.
XGEVA segment is expected to grow at a lucrative growth rate over the forecast period. This can be attributed to supportive reimbursement policies for XGEVA for the treatment of women with bone disease in the U.S. Currently, people with need of XGEVA for disease can get drugs at low cost through available co-pay or insurance coverage programs, such as prescription discount programs, Amgen SupportPlus Co-Pay Program, and NeedyMeds for U.S. people. These programs offer drugs at low cost to required patients and help address unmet market demand and drive segment growth.
The other segment held a considerable market share of 59.35% in 2023. This can be attributed to the rising population of women below the age of 50 years. Women aged below 50 years are mainly in the reproductive age, and women’s health issues associated with this age group are more likely related to fertility, such as hormonal infertility, endometriosis, and PCOS. In the U.S., about 30% of menstruating women, along with 42% of young & pregnant women, were reported to be iron deficient, which can be attributed to monthly blood loss. This is expected to boost the demand for therapeutic drugs, thereby driving the market growth during the forecast period.
The 50-year-old & above-age segment is expected to register the fastest growth rate over the forecast period. Women aged 50 & above form the core demographic for the likelihood of menopause, and hence, the adoption of postmenopausal products is higher within this segment. According to the National Academy of Medical Science (NAMS) stated that every day in the U.S., an estimated 6,000 women reach menopause, which means over 2 million women reach menopause every year. All these factors are expected to drive the growth of this segment in the years to come.
Some key players operating in the market boast an extensive product portfolio encompassing a wide array of women’s health solutions, catering to a diverse consumer base. This broad coverage intensifies competition among leading companies, ultimately impacting profitability due to heightened competitive pressures.
TherapeuticsMD, Inc. and Mithra Pharmaceuticals are some emerging market participants in the Market. These players usually focus on strategic collaborations and partnerships with leading players to diversify and attain a position in the market.
In April 2024, Cleveland Clinic launched its new Women’s Comprehensive Health and Research Center dedicated to helping women with women during midlife get specialized care. The launch health center for women's treatment is expected to boost market growth in the U.S.
In March 2024, the U.S. FDA approved Jubbonti/ Wyost (denosumab) developed by Sandoz, the first biosimilar to reference Amgen’s Prolia/ Xgeva (denosumab) in the U.S. This drug is indicated for the treatment of adults with hypercalcemia and osteoporosis as well as prevent skeletal-associated events with condition of bone metastases from solid tumors.
In June 2023, Pfizer Inc. announced the restock of DUAVEE, an estrogen-based menopause hormone therapy in the U.S.
Report Attribute |
Details |
Market size value in 2024 |
USD 24.27 billion |
Revenue forecast in 2030 |
USD 29.68 billion |
Growth rate |
CAGR of 4.04% from 2024 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Application, age, drug |
Country scope |
U.S. |
Key companies profiled |
AbbVie, Inc.; Bayer AG; Merck & Co., Inc.; Pfizer, Inc; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; Amgen, Inc; Apothecus Pharmaceutical Corp.; Eli Lilly and Company; Ferring B.V. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the U.S. Women’s Health Market, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. women’s health market report based on the application, drugs, and age:
Application Outlook (Revenue, USD Million, 2018 - 2030)
Hormonal Infertility
Contraceptives
Postmenopausal Osteoporosis
Endometriosis & Uterine Fibroids
Menopause
Polycystic Ovary Syndrome (PCOS)
Drug Outlook (Revenue, USD Million, 2018 - 2030)
ACTONEL
YAZ, Yasmin,Yasminelle
FORTEO
Minastrin 24 Fe
Mirena
NuvaRing
ORTHO TRI-CY LO
Premarin
Prolia
Reclast/Aclasta
XGEVA
Zometa
Others
Age Outlook (Revenue, USD Million, 2018 - 2030)
50 years and above
Postmenopausal Osteoporosis
Endometriosis & Uterine Fibroids
Menopause
Others
Others
b. The U.S. women’s health market size was estimated at USD 22.50 billion in 2023 and is expected to reach USD 24.27 billion in 2024.
b. The U.S. women’s health market is expected to grow at a compound annual growth rate of 4.04% from 2024 to 2030 to reach USD 29.68 billion by 2030.
b. The Prolia segment held the largest market share of 19.92% in 2023 and is anticipated to grow at the fastest growth rate over the forecast period in U.S. women’s health market. Prolia is a medication used in the field of women's health for the treatment and prevention of osteoporosis in postmenopausal women.
b. Some key players operating in the U.S. women’s health market include AbbVie Inc., Merck & Co., Inc. (ORGANON), Amgen, Inc., Agile Therapeutics, Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Apothecus Pharmaceutical Corp., Pfizer, Inc., Lilly (Eli Lilly), and Ferring B.V.
b. Key factors that are driving the market growth include the rising prevalence of women’s health-related conditions, increasing government and various organizations initiatives, and rising funding from public organizations in family planning services.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."